Dexcom, Inc. DXCM

Revenue Intelligence Report • 62 quarters of SEC filing data • Updated 2026-03-06

Dexcom, Inc. demonstrates strong revenue growth driven by strategic investments in R&D and SG&A, with elasticities of 1.72% and 1.66%, respectively, indicating a robust return on investment for these expenditures. The company reported a quarterly revenue of $1.26 billion, with a fiscal year forecast of $6 billion, reflecting a 20.2% year-over-year increase. Despite a slight prediction error of 2.9% in its holdout test, the model's accuracy remains solid at 5.5% MAPE, underscoring the reliability of its revenue projections. Overall, Dexcom's focus on innovation and effective spending positions it well for continued growth in the competitive healthcare market.

Next FY Revenue

$5.60B

+20.2% YoY

R&D Elasticity

1.72x

SG&A Elasticity

1.66x

Model Accuracy

5.5% MAPE

Holdout validation: The model predicted $1B vs the actual $1B — an error of 2.9%.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$1B	$1B	$1B – $1B	+16.4%	✓ In range
Q2 2026	$1B		$1B – $2B	+24.4%
Q3 2026	$1B		$1B – $2B	+18.2%
Q4 2026	$1B		$1B – $2B	+17.5%
Q1 2027	$2B		$1B – $2B	+21.1%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch